RSV Lower Respiratory Tract Illness in Infants of Low- and Middle-income Countries

Area of Science:

• Pediatrics
• Infectious Diseases
• Public Health

Background:

• Respiratory syncytial virus (RSV) lower respiratory tract illness (LRTI) is a major global cause of infant morbidity and mortality.
• The burden of RSV LRTI is significantly higher in developing countries compared to industrialized nations.
• Current preventive measures like palivizumab face challenges in routine use due to cost and administration requirements.

Purpose of the Study:

• To review and highlight the disparities in RSV LRTI outcomes between industrialized and developing countries.
• To identify factors contributing to the differential impact of RSV infection in diverse global settings.
• To underscore the need for targeted prevention strategies based on population-specific risk factors.

Main Methods:

• This study is a review of existing literature and data on RSV LRTI.
• It analyzes and compares epidemiological data and clinical outcomes from different economic settings.
• Observations on the consequences of viral infection in various environments are presented.

Main Results:

• RSV LRTI poses a substantial threat globally, with mortality concentrated in developing countries.
• A significant disparity exists in mortality rates between low- and high-income countries.
• The effectiveness of palivizumab is limited by its cost and dosing schedule, hindering widespread adoption.

Conclusions:

• RSV LRTI remains a critical health issue in both industrialized and developing nations, with a higher mortality toll in the latter.
• Advancements in vaccines and monoclonal antibodies are progressing through late-stage trials, offering future hope.
• The next decade is anticipated to bring significant changes in the management and prevention of RSV infections in infants.